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Dilated Cardiomyopathy
ABSTRACT 
Objective: To evaluated possible clinical and instrumental, natural history and prognostic divergences in women and 
men with idiopathic dilated cardiomyopathy (IDCM).
Patients and Methods: From 1988 to 2012, we evaluated 803 consecutive patients with IDCM recorded in the 
Heart Muscle Disease Registry of Trieste (Italy). All patients had serial follow-up evaluations at 6, 12, and 24 months, 
and subsequently every two years, or more frequently if clinically indicated.
Results: Two hundred and twenty-seven patients (28%) were female. At first evaluation women were significantly older 
(48 vs. 45 years old, p = 0.008); presented more frequently left bundle branch block at ECG (38% vs. 28%, p = 0.01), 
smaller left ventricular end-diastolic indexed volume at echocardiography (85 vs. 93 ml/m2, p <0.002) and more 
frequently moderate to severe mitral regurgitation at Doppler (43% vs. 33%, p = 0.015). No differences in NYHA class, 
medical treatment and device implantation rates were found. During a median of 108 months follow-up, women showed a 
significantly lower ten-year total mortality/heart transplantation (20% vs. 32% respectively, p = 0.001) and cardiovascular 
mortality rates (9% vs. 15%, p = 0.024) despite a less marked clinical and echocardiographic improvement. 
Conclusion: In our population of patients with IDCM, women showed a better long-term prognosis notwithstanding 
a presentation with a more advanced disease and a lower clinical-instrumental improvement on optimal medical 
therapy compared to men. 
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INTRODUCTION
Several gender differences exist in normal heart 
anatomy and physiology. In fact men have an increased 
left ventricle (LV) indexed mass, but female myocardial 
mass is better preserved with aging [1]; coronary vessels 
are smaller and LV ejection fraction (LVEF) is higher in 
women compared to men. Moreover, premenopausal 
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women have lower blood pressure, faster resting heart rate 
and longer QTc interval than men [2]. 
Clinical and experimental evidence suggests that 
the pathogenesis and prognosis of many cardiovascular 
diseases differ between genders.
Idiopathic dilated cardiomyopathy (IDCM) can be 
considered the most genetically heterogeneous cardiac 
disease, with mutations in more than 50 single genes 
encoding cytoskeletal, nuclear skeletal, mitochondrial, 
and calcium-handling proteins [3,4]. Most of the genes 
implicated are autosomal, with primarily dominant 
transmission. However, other causes of IDCM (i.e. 
inflammatory or autoimmune) exist and preliminary data 
suggest that gender-related variations may account for some 
differences in epidemiology, left ventricular recovery, and 
survival between men and women with post-myocarditis 
IDCM, highlighting knowledge gaps in management of 
women with acute IDCM [3].
IDCM has a slight greater prevalence in men than in 
women; recent trials and registries report a female/male 
ratio between 1:1.3 and 1:1.5 [3,4], anyway there are 
few information about clinical-instrumental and prognostic 
gender differences in this specific setting.
The present investigation wanted to provide an insight 
into clinical, laboratory, echocardiographic, long-term 
evolution and prognostic divergences in the natural history 
of women and men with IDCM.
METHODS
Study population
In our study we evaluated patients with IDCM enrolled 
in the Heart Muscle Disease Registry of Trieste (Italy) from 
January 1st 1988 to December 31st, 2012. Although data 
were retrospectively analysed, patients were prospectively 
included in the Registry. 
We considered patients referred to our Center in both 
acute instable clinical condition and stable clinical status. 
At enrolment, a physical examination, 12-lead 
electrocardiogram (ECG), transthoracic echocardiogram 
and 24-hour Holter-ECG monitoring were performed. All 
patients >35 years old underwent coronary angiography 
to exclude a significant coronary artery stenosis (>50% in 
a major vessel). Until 1996, patients routinely underwent 
endomyocardial biopsy in order to exclude an active 
myocarditis. Thereafter, biopsies were performed only in 
those patients presenting with recent (<6 months) onset of 
heart failure and/or clinical history and instrumental findings 
suggesting active myocarditis, severe LV dysfunction without 
significant ventricular remodeling on echocardiography or 
left bundle branch block at ECG, and/or idiopathic major 
ventricular arrhythmias at presentation. 
IDCM diagnosis was defined according to the World 
Health Organization criteria. Enrolled patients presented 
left ventricular (LV) ejection fraction <50% at baseline 
evaluation in absence of any of the following conditions: 
history of blood pressure >160/100 mmHg, obstruction 
>50% of a major coronary artery branch (at coronary 
angiography), alcohol intake >100 g/day, advanced 
systemic disease affecting short-term prognosis, pericardial 
diseases, congenital heart diseases, cor pulmonale, active 
myocarditis, aortic valve disease and organic mitral valve 
disease . Persistent high-rate supraventricular arrhythmias 
were considered an exclusion criteria when documented 
in the six months before the enrolment.
All familial IDCM cases fulfilled the published 
criteria(4).
Since 1988, after careful stabilization on optimal 
dose of ACE-inhibitors, besides digitalis and diuretics, 
patients were treated with beta-blockers (metoprolol 
tartrate, carvedilol or bisoprolol).
Medical treatment for IDCM was considered optimal 
when the maximal tolerated dose of beta-blockers and 
ACE-inhibitors was administered: in order to achieve 
this condition, low doses of beta-blockers and ACE-
inhibitors were tested and slowly up-titrated to the highest 
dosage tolerated within 2-3 months. The daily dosages 
of ACE-inhibitors and beta-blockers were reported as 
enalapril and carvedilol-equivalents, respectively [5] . 
Anti-aldosterone agents were given only for potassium 
sparing intent and, after the publication of the Randomized 
Aldactone Evaluation Study (RALES) [6] to patients with 
persisting severe heart failure despite the optimization of 
medical treatment. Amiodarone was administered in the 
presence of frequent and/or symptomatic ventricular or 
supraventricular arrhythmias. No other antiarrhythmic drugs 
were given.
From 1998 all high-risk patients with IDCM were 
treated with an implantable cardioverter defibrillator (ICD) 
for primary prevention adding cardiac resyncronization 
therapy (CRT) according to the current guidelines at the 
time of enrolment or follow-up. A CRT device was routinely 
implanted in our patients after 2005. Patients had serial 
follow-up evaluations at the Heart Failure Outpatient Clinic 
of the Cardiology Department of Trieste at 6, 12, and 
24 months, and subsequently every two years, or more 
frequently if clinically indicated.
We considered and compared some clinical, 
laboratory, electrocardiographic and echocardiographic 
characteristics between men and women at baseline, and 
then we evaluated the longitudinal changes of the most 
relevant parameters in different steps during follow-up.
The primary measurement of outcome of the study 
was long-term total death/ heart transplantation (D/HTx) 
and the secondary endpoints were cardiovascular death 
(CVD), heart failure death, unexpected sudden cardiac 
death and unexpected sudden cardiac death/ major 
ventricular arrhythmias/appropriate ICD interventions (SD/
MVA/AII).
Urgent heart transplantation was considered for 
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patients with refractory heart failure requiring inotropic 
treatment and/or mechanical support.
SD was defined as an immediate death or a death 
occurring within 1 hour after the onset of symptoms or 
during sleep in stable NYHA I-III functional class patients. 
Statistical Analysis
Study design, data analysis and reporting were 
performed according to the “Strengthening the Reporting 
of Observational Studies in Epidemiology” (STROBE) 
guidelines [7]. This study was performed in accordance 
with the guidelines set by the Declaration of Helsinki 
[8] and with the local legal requirements. Descriptive 
statistics of clinical and instrumental parameters are 
reported as median and interquartile range or number 
and percentages, respectively for continuous and discrete 
variables. To investigate for gender differences, both at 
baseline and cross-sectionally at different follow up visits, 
continuous parameters were compared by means of the 
ANOVA test if Gaussian distributed or the non parametric 
Median test if not; the Chi-square or Fisher exact test were 
applied for discrete parameters. Variations in repeated 
measures in each group were evaluated for continuous 
parameters by means of paired t-test if Gaussian distributed 
or the non parametric Friedman test if not; the Mc Nemar 
test was used for binary parameters. 
Survival curves were calculated according to the 
Kaplan Meier method and the comparison between 
groups was carried out with the Log Rank test. We 
also estimated the cumulative incidence functions of two 
specific competing risk (sudden cardiac death/major 
ventricular arrhythmias/ appropriate ICD intervention 
vs pump failure death/heart transplant) and tested for 
differences between males and females. All results were 
considered as statistically significant when the p value was 
<0.05. The entire analysis was performed using the SPSS 
package, version 13.0 (SPSS Inc., Chicago, Illinois, USA) 
and the R package version 3.01 package cmprsk.
RESULTS
Baseline characteristics
Study population counted 803 consecutive patients 
with IDCM. Of these 227 (28 %) were women. The 
baseline clinical and instrumental characteristics of the 
overall population are shown in Table 1. 
At enrolment, women resulted significantly older 
compared to men [48 (37-58) vs. 45 (34-55) years old 
respectively,p=0.008], with lower haemoglobin values 
[12.9 (12.1-13.9) vs. 14.6 (13.8-15.4) g/dL, p<0.001] 
and lower glomerular filtration rate [66 (56-75)vs.115 
(93-139) mL/min, p<0.001].
Regarding ECG evaluation, women presented more 
frequently with left bundle branch block (38% vs. 28%, 
p=0.01).
Considering echocardiographic measurements 
women showed a significantly greater left ventricular end-
diastolic indexed diameter [36 (33-40) vs. 34 (31-38) 
mm/m2; p<0.001], but a slight smaller end-diastolic 
volume index [85 (67-111) vs. 93 (75-120) ml/m2; 
p=0.002], and more frequently a moderate to severe 
mitral regurgitation at Doppler (43% vs. 33%; p=0.015). 
No significant differences were observed in baseline 
NYHA class, duration of heart failure and pharmacological 
treatment after first evaluation and device implantation 
during follow-up: 88% of women and 92% of men 
received angiotensin-converting enzyme inhibitors or 
angiotensin receptor blockers (p=0.054) and 80% of 
women and 81% of men received beta-blockers (p= ns); 
13% of women and 18% of men received an ICD (p=ns), 
and 8% of women and 5% of men a CRT device (p=ns).
Long-term follow-up trends
In the first 6 months of follow-up, a higher percentage 
of men compared to women improved clinically gaining 
NYHA class I, whereas more women maintained a NYHA 
classes III-IV (see trends in Supplementary Table 1). The 
NYHA class improvement among men was maintained 
stable up to the 72 months follow-up, but subsequently 
a significant worsening was observed (p<0.001). 
Conversely, women showed no significant variation in 
NYHA class during the entire follow-up (Figure 1). 
Considering echocardiographic parameters, a higher 
quota of women showed a significant mitral regurgitation 
and a restrictive pattern during the first 24 months of 
follow-up; subsequently a similar trend was observed 
for the frequency of these parameters in both genders. 
Women showed a larger index diastolic diameter during 
the whole long-term follow-up (Figure 1). Considering the 
evolution of LVEF, a significant improvement was observed 
in both genders at 12 months (p<0.001); thereafter, a 
further improvement at 24 months was documented only 
in men (p=0.011), followed by a worsening after 72 
months. Conversely, LVEF remained stable in women at 
long-term follow-up. (see trends in Supplementary Table 1 
and Supplementary Table 2). 
Both total mortality/heart transplantation and 
cardiovascular mortality at 20 years resulted significantly 
lower in women than in men (20% vs. 32% p=0.001 
and 9% vs. 15% p=0.024, respectively). Considering 
heart failure mortality, unexpected sudden cardiac death 
and unexpected sudden cardiac death/major ventricular 
arrhythmias/appropriate ICD intervention, there was a 
trend of a lower rate of events in women (Table 2, Figures 
2,3) Moreover the appropriate test in order to compare 
the cumulative incidence of a competing risk showed no 
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Age (y) 45 45 (34-55) 48 (37-58) 0.008
Weight (kg) 74 (65-84) 78 (70-87) 64 (56-71) < 0.001
Height (cm) 171 (165-178) 174 (170-180) 163 (160-168) < 0.001
Body mass index (kg/m2) 25.3 (22.7-27.9) 25.7 (23.3-28.0) 24.0 (21.6-26.8) < 0.001
Body surface area (m2) 1.9 (1.8-2.0) 1.9 (1.8-2.1) 1.7 (1.6-1.8) < 0.001
Family history 14 (18%) 98 17% 43 19% ns
Heart rate at rest (beats/min) 75 (68-87) 75 (68-85) 76 (70-90) ns
Systolic blood pressure (mmHg) 120 (110-135) 125 (110-135) 120 (110-140) ns
NYHA I 277 (34.6%) 209 (36%) 68 (30%)
II 327 (41%) 231 (40%) 96 (42%) ns
III 152 (19%) 103 (18%) 49 (22%)
IV 44 (5.5%) 31 (5%) 13 (6%)
NYHA III-IV 196 (24.5%) 134 (23.3%) 62 (27.4%) ns
Heart Failure duration (y) 1 (0-7) 1 (0-7) 1 (0-8.5) ns
Laboratory findings
Haemoglobin (mg/dL) 14 (13-15) 14.6 (13.8-15.4) 12.9 (12.1-13.9) < 0.001
GFR (ml/min) 102 (76-130) 115 (93-139) 66 (56-75) < 0.001
Potassium (mEq /L) 4.2 (4-4.5) 4.2 (4.0-4.5) 4.2 (3.9-4.5) ns
Creatinine (mg/dL) 1.1 (0.9-1.2) 1.1 (1.0-1.2) 0.9 (0.8-1.1) <0.001
Diabetes mellitus 51 (6%) 39 (7%) 12 (5 %) ns
Electrocardiographic findings
Sinus rhythm 697 (89.5 %) 489 (87.5 %) 208 (94.5 %) 0.004
RBBB 136 (17.6 %) 88 (15.9%) 48 (21.7%) 0.055
LBBB 242 (31.2%) 158 (28.5%) 84 (38%) 0.01
QRS duration (msec) 90 (80-100) 80 (80-100) 100 (80-130) ns
QTC (msec) 437 (403-468) 433 (400-466) 440 (411-476) ns
QT (msec) 400 (360-420) 400 (360-420) 400 (360-440) ns
VEB/ 24h monitoring 19 (1-101) 21 (1-103) 16 (1-93) ns
Ventricular Couplets/ 24h 1,2 (0.0-1.5) 0.1 (0-1.6) 0,1 (0-1.4) ns
Ventricular tachycardias / 24h 0,0 (0.0-0.1) 0 (0-0.1) 0 (0-0.1) ns
Echocardiographic findings
LVEF (%) 32 (24-39) 32 (24-39) 31 (24-41) ns
LVEF < 30 324 (45 %) 229 (44 %) 95 (46,8 %) ns
LVEF < 35 445 (61.6 %) 318 (61.3 %) 127 (62.6 %) ns
Indexed LVEDD (mm/m2) 35 (30-41) 34 (31-38) 36 (33-40) < 0.001
Indexed LVESD (mm/m2) 29 (23-34) 29 (24-33) 29 (26-33) 0.05
Restrictive filling pattern 184 (28 %) 140 (29 %) 44 (25.4 %) ns
Moderate-severe MR 271 (36 %) 180 (33.5 %) 91 (42.9 %) 0.015
Indexed LVEDV (mL/m2) 91 (72-117) 93 (75-120) 85 (67-111) 0.002
Indexed LVESV (mL/m2) 63 (44-86) 64 (46-89) 57 (40-81) 0.008
Indexed Left atrium diameter (mm/m2) 19 (15-23) 19 (15-23) 20 (13-24) ns
Indexed left atrium area (cm2/m2) 13 (10-16) 13 (10-16) 13 (11-16) ns
Drug therapy
Enalapril equivalent dosage (mg/day) 18 (10-20) 20 (10-20) 13 (10-20) ns
Carvedilol equivalent dosage (mg/day) 25 (20-75) 37.5 (20-75) 25 (20-50) ns
Anti-arrhythmics 156 (19.4 %) 117 (20.3%) 39 (17.2%) ns
Diuretics 393 (49 %) 283 (49%) 110 (48.5%) ns
Potassium-sparing diuretics 47 (6.1 %) 36 (6.5%) 11 (5%) ns
Beta-blockers 653 (81.2 %) 470 (81.5%) 183 (80.6%) ns
ACE inhibitors 730 (91 %) 531 (92%) 199 (87.7%) ns
Digoxin 451 (56.1%) 332 (57.5%) 119 (52.4%) ns
Devices
CRT 49 (6.1%) 30 (5.2%) 19 (8.4%) ns
ICD 132 (16.4%) 102 (17.7%) 30 (13.2%) ns
NYHA, New York Heart Association class; GFR, Glomerular filtration rate; LVEF, Left ventricular ejection fraction; LVEDD, Left ventricular end-diastolic 
diameter; LVESD, Left ventricular end-systolic diameter; MR, mitral regurgitation; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic 
volume; RBBB, Right bundle branch block; LBBB, Left bundle branch block; CRT Cardiac resynchronization therapy; ICD Implantable cardiac defibrillator.
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FIGURE 3. Cardiovascular death free survival.
FIGURE 1. Longitudinal trends during follow-up. Red lines are for females and black lines are for males. NYHA: New York Heart 
Association class; LVEF: Left ventricular ejection fraction; LVEDD: Left ventricular end-diastolic diameter; LVEDV: left ventricular 
end-diastolic volume; MR: mitral regurgitation; RFP: restrictive filling pattern.
TABLE 2. Events
All
( N = 803 )
Males
( N= 576, 72 % )
Females
( N=227, 28% )
P value
(Kaplan- Meier)
Mean follow-up (months) 108 108 108
All cause mortality/heart transplant n(%) 233 (29%) 187 (32.5%) 46 (20.3%) 0.001
Heart transplant n (%) 69 (8.6%) 54 (9.4%) 15 (6.6%) ns
Cardiovascular death n (%) 110(13.7%) 89 (15.4%) 21 (9.3%) 0.014
Pump failure death n (%) 47 (5.8%) 37 (6.4%) 10 (4.4%) ns
Unexpected sudden death n (%) 68 (8.5%) 55 (9.5%) 13 (5.7%) ns
Unknown cause death n ( % ) 29 (3.6%) 24 (4.2%) 5 (2.2%) ns
Appropriate intervention of ICD N=40
N (% of implanted patients 132: 102 men, 30 women) 40 (30%) 29/102 (28%) 11/30 (37%) ns
FIGURE 2. Total death/ heart transplantation free survival.
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significant differences between genders (for SD/MVA/
AII p=0,10; for pump failure death/HTx p=0,286) 
(Supplementary figure 4). 
In order to understand the role of fully optimized 
medical therapy, including anti-aldosterone and the 
progressive use of device therapy that increased in the 
last decade, we analyzed the long-term results before and 
after 1998: women maintain a survival benefit compared 
to men in both periods (Supplementary figure 5).
DISCUSSION
This study analysed a single-center, large, well 
delineated population of patients affected by IDCM who 
were enrolled in the Heart Muscle Disease Registry of 
Trieste and regularly followed since 1988. Our data 
confirmed the epidemiological higher prevalence of male 
gender in IDCM and newly demonstrated that, even if 
male patients showed more frequently than women a 
clinical and echocardiographic improvement, they have 
a worse long-term evolution of the disease in terms of 
left ventricular impairment and total and cardiovascular 
mortality.
Gender differences have been described in different 
heart failure populations in clinical trials and registries 
[9-13]; aetiology is different with a prevalence of ischemic 
heart disease and IDCM in men whereas hypertension 
and valvular heart disease are frequent risk factors in 
women. Women with heart failure (HF) present more often 
with preserved or mildly depressed systolic function than 
men, notwithstanding, women have a lower quality of life 
with a more pronounced functional capacity impairment, 
comorbidities and depressed mental status [14-17] . 
Nevertheless, women with HF have a better survival but 
the reason still remains unclear; some authors suggest 
that it might be related to sex differences in aetiology 
and in pathophysiology, pointing out neuro-hormonal and 
inflammation divergences between genders [16,18]. 
Anyway, aetiology has not been confirmed as a 
gender-specific prognostic risk factor. In fact, in the analysis 
of CHARM trial, which compared the outcomes of 2400 
women to 5199 men randomized to candesartan therapy, 
women had a better survival than men, independently from 
the cause of heart failure, age and LVEF [19]. In addition, 
the MADIT-CRT study demonstrated a striking difference in 
survival between men and women, the latter presenting 
with a better reverse cardiac remodelling and prognosis; 
these results have been interpreted as probably due to 
the higher prevalence of IDCM and to the more frequent 
left bundle branch block in women. Even in the subset 
of MADIT-CRT patients with LBBB, females had a more 
relevant benefit with respect to males after adjustment for 
covariates [20].
From a public health and management point of 
view, large series of patients with HF show greater 
underutilisation of guideline based HF therapy in women 
[21]; in our population medical therapy uptitration was 
equally performed in both sexes, that allowed us to avoid 
any gender discrimination in our analysis. 
At the best of our knowledge this is the largest study 
that analysed gender differences in an homogeneous 
population with IDCM.
There are only few and aged studies that consider 
the specific setting of gender differences in IDCM. Two 
decades ago, De Maria et al., reporting data from 303 
patients with IDCM, concluded that women had a longer 
duration of disease before diagnosis and consequently 
presented with a more advanced phase of cardiomyopathy 
with a greater LV dilatation, but did not have a different 
prognosis than men [22]. 
Further information came from the IMAC-2 study 
(Intervention in Myocarditis and Acute Cardiomyopathy), 
which investigated new clinical and demographic 
predictors of outcome for subjects with recent onset dilated 
cardiomyopathy. In that study, women demonstrated a 
more favourable prognosis; however the Authors drove 
their attention to racial rather than to gender differences, 
underlining that recovery and survival were poorer in black 
subjects [23]. 
Recently published results from our group in a selected 
cohort of patients with IDCM and at least 10 years of 
follow-up identified the male gender as a predictor of 
adverse outcome and identified the absence of LBBB 
and a higher blood pressure as features predictive for left 
ventricular reverse remodeling [24]. 
Interestingly, in our population women presented 
more often with left bundle branch block, that could 
suggest a more pronounced electrical and myocardial 
disease, anyway, women demonstrated a better prognosis 
than men during follow-up. In our population we have 
found also interesting data regarding left ventricular shape, 
in fact women presented a larger indexed diameter and 
smaller indexed volumes: these apparently conflicting 
results may be expression of a different left ventricular 
remodeling and reshaping in women with IDCM and be 
another explanation for the better natural history of this 
disease in female gender. 
A possible interpretation for different gender-related 
prognosis in heart failure can be found in the sex-
related differences in the inflammatory and biochemical 
remodeling process. A recent study by Meyer et al. 
investigated a cohort of 567 patients enrolled in the 
COACH (Coordinating study evaluating Outcomes of 
Advising and Counseling in Heart failure) with heart failure 
(ischemic aetiology in 41% of patients) and evaluated 
serum biomarkers related to inflammation, extracellular 
matrix remodelling, cardiomyocyte stretch, angiogenesis 
and oxidative stress. Interestingly, female patients had 
a better prognosis and their levels of biomarkers related 
to inflammation and remodeling were significantly lower 
[25]. Several animal models and some human studies 
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on myocardial injury, as well as on pressure and volume 
overload, demonstrated that female gender is reliably 
associated with a slowed and attenuated development 
of adverse cardiac remodelling and heart failure [26-
28]. In particular, men are more prone to remodel with 
LV dilatation and fibrosis, while women more frequently 
remodel with marked concentric hypertrophy and smaller 
cavity volumes [29]. These findings could suggest an 
explanation for the prevalence of heart failure with 
preserved EF in women. Moreover, sex-differences in 
inflammatory and remodelling process can be attributed 
also to the effects of sexual hormones, in particular 
oestrogens/progesterone balance, on the corresponding 
pathophysiological pathways. According to recent studies, 
sex hormones seem to be correlated to the subsequent 
risk of chronic dilated cardiomyopathy after heart injury 
[3]. Sex steroid hormones are able to directly affect 
cardiac function, endothelial cell function, and vascular 
tone through genomic and non-genomic effects of the 
androgen and oestrogen receptors, which are present on 
vascular endothelial and smooth muscle cells as well as on 
cardiac fibroblasts, myocytes, and platelets with a different 
distribution according to gender [30]. These underlying 
sex differences in cardiac function and physiology may 
influence the immune response to inflammation and injury 
in the heart. The role of neuro-hormonal pattern has not 
yet been investigated in the specific subset of IDCM; 
notwithstanding that we could argue that sex-differences in 
clinical response, echocardiographic reverse remodelling 
and outcome in IDCM could be influenced by neuro-
hormonal status translating results from heart failure models 
and ischemic heart disease remodelling. 
Our results confirmed the previous information about 
gender differences in heart failure demonstrating the better 
prognosis of women also in the IDCM subset. IDCM 
usually affect young people with few comorbidities, so it 
delineates an ideal model of heart failure. In this context, 
further studies evaluating genetic and molecular differences 
between genders might be important to understand the 
different clinical behavior and prognosis between men 
and women.
Study Limitations 
The observational studies on long-term registries 
usually suffer from the common bias of different protocols 
and treatment. However, different therapeutic strategies in 
presence of the same inclusion criteria overtime at the same 
institution could represent an advantage for the present 
analysis. Moreover, the current study population was 
enrolled in a tertiary referral center for cardiomyopathies 
and heart failure, thus imposing a selection bias with respect 
to the characteristics of IDCM in the general population. 
We included heart transplantation in the composite end-
point even if it is not a fatal event. In our opinion, it remains 
a major event in the natural history of IDCM, which has 
the same impact of death in the prognostic evaluation of 
the disease, especially considering that only urgent heart 
transplantation were included.
Interesting information in order to understand gender 
differences could arise from cardiac magnetic resonance 
imaging or from laboratory data (i.e. BNP and genotypic 
characterizations) that has not been systematically 
performed in all our populations considering that the 
enrollment started in 1988. These additional evaluations 
should be assessed in future dedicated prospective 
investigation.
Finally, our population included only patients with 
IDCM: the results therefore should not be extended to 
patients with other causes of impaired LVEF, such as 
hypertension or ischemic heart disease. 
CONCLUSIONS
In our population, women with ICDM presented 
at enrollment a clinical and instrumental severity of 
the disease comparable to men and remain stable 
during follow-up in optimal medical treatment or device 
therapy, whereas men demonstrated a better response 
in terms of clinical features and echocardiographic LVRR 
but a worse prognosis regarding long-term total and 
cardiovascular mortality. 
To the best of our knowledge this is the first 
epidemiological study that analyses sex-differences in a 
large homogeneous population of patients with IDCM 
enrolled in a tertiary center and followed up to more than 
two decades. Further studies are required to confirm our 
data on larger multicentric patient populations in order to 
assess the mechanisms underlying the natural history and 
prognostic gender-related differences. 
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